Vancive Medical Technologies™ and CareFusion Corporation CFN
today announced an exclusive agreement in the United States, Canada and
Mexico for the licensing and distribution of Vancive's BeneHold™
Chlorhexidine Gluconate (CHG) antimicrobial Adhesive Technology for
applications in vascular access.
Under the agreement, CareFusion will market Vancive's unique
antimicrobial adhesive technology used with transparent dressings that
are ideally suited for protection of catheter insertion sites. The first
product received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) in September 2012 and will be co-branded under
CareFusion's new ChloraShield™ brand.
“We are excited about this collaboration, and believe it is an excellent
opportunity
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in